MX2023009613A - Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta. - Google Patents

Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta.

Info

Publication number
MX2023009613A
MX2023009613A MX2023009613A MX2023009613A MX2023009613A MX 2023009613 A MX2023009613 A MX 2023009613A MX 2023009613 A MX2023009613 A MX 2023009613A MX 2023009613 A MX2023009613 A MX 2023009613A MX 2023009613 A MX2023009613 A MX 2023009613A
Authority
MX
Mexico
Prior art keywords
obicetrapib
ezetimibe
hyperlipidemia
combination therapy
patients suffering
Prior art date
Application number
MX2023009613A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Jacob Pieter Kastelein
Marc Ditmarsch
Michael Harvey Davidson
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of MX2023009613A publication Critical patent/MX2023009613A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2023009613A 2021-02-18 2022-02-18 Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta. MX2023009613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2021050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (1)

Publication Number Publication Date
MX2023009613A true MX2023009613A (es) 2023-11-09

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009613A MX2023009613A (es) 2021-02-18 2022-02-18 Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta.

Country Status (11)

Country Link
US (1) US20240189311A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294387A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507810A (cg-RX-API-DMAC7.html)
KR (1) KR20230159380A (cg-RX-API-DMAC7.html)
CN (1) CN117042770A (cg-RX-API-DMAC7.html)
AU (1) AU2022223224A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016682A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210033A1 (cg-RX-API-DMAC7.html)
IL (1) IL304544A (cg-RX-API-DMAC7.html)
MX (1) MX2023009613A (cg-RX-API-DMAC7.html)
WO (1) WO2022177428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
EP4661865A1 (en) * 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CN119499252A (zh) * 2014-02-05 2025-02-25 新阿姆斯特丹制药私人有限公司 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
CN104382896A (zh) * 2014-11-04 2015-03-04 万全万特制药江苏有限公司 含有依折麦布和辛伐他汀的药物组合物
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
IL318925A (en) * 2022-08-22 2025-04-01 Newamsterdam Pharma B V Combination therapy with ovistrefib and ezetimibe and fixed-dose pharmaceutical preparations

Also Published As

Publication number Publication date
JP2024507810A (ja) 2024-02-21
KR20230159380A (ko) 2023-11-21
CA3210033A1 (en) 2022-08-25
WO2022177428A1 (en) 2022-08-25
AU2022223224A1 (en) 2023-08-24
IL304544A (en) 2023-09-01
US20240189311A1 (en) 2024-06-13
BR112023016682A2 (pt) 2023-11-14
CN117042770A (zh) 2023-11-10
EP4294387A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
MX2024003922A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos.
BR112023016682A2 (pt) Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
EP4119156A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
MY199903A (en) Combination therapy with controlled-release cnp agonists
MX2023013403A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
EP4360649A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
MX2025001876A (es) Tratamiento de combinacion de obicetrapib y ezetimiba y composiciones farmaceuticas de dosis fija
EP4119157A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
PH12022551094A1 (en) Novel insulin analogues and uses thereof
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias
MX2025002176A (es) Inhibidores de tyk2 y usos de los mismos
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
PH12021550656A1 (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
ZA202212363B (en) Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19
WO2023183405A3 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
EP4349339A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND ITS USE
MX2022015279A (es) Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.
IL295948B1 (en) A pharmaceutical preparation for the prevention or treatment of diabetes and related metabolic diseases
HK40105287A (en) Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
MX2022010628A (es) Composicion para la prevencion y tratamiento de la disbiosis.
CA3277833A1 (en) Medicament for treatment and/or prevention of cancer
CA3264839A1 (en) Medicament for treatment and/or prevention of cancer